Home
>
US Stocks
>
DURECT Corp

DURECT Corp (DRRX)

$6.43

+0.41

(+6.81%)▲

Live

Insights on DURECT Corp

  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 11.97M → 2.05M (in $), with an average decrease of 55.2% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, -2.47M → -11.98M (in $), with an average decrease of 169.1% per quarter

Performance

  • $6.09
    $6.71
    $6.43
    downward going graph

    5.26%

    Downside

    Day's Volatility :9.14%

    Upside

    4.1%

    downward going graph
  • $3.17
    $9.70
    $6.43
    downward going graph

    50.7%

    Downside

    52 Weeks Volatility :67.32%

    Upside

    33.71%

    downward going graph

Returns

Period DURECT CorpRussel 2000Index (Russel 2000)
3 Months
18.97%
-6.7%
-6.7%
6 Months
43.37%
-6.2%
-6.2%
1 Year
994.55%
-6.3%
-6.3%
3 Years
145.71%
26.9%
26.9%

Highlights

Market Capitalization
147.4M
Book Value
$0.63
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-1.56
PEG Ratio
-0.46
Wall Street Target Price
36.25
Profit Margin
-187.82%
Operating Margin TTM
-184.01%
Return On Assets TTM
-32.17%
Return On Equity TTM
-115.9%
Revenue TTM
19.4M
Revenue Per Share TTM
0.84
Quarterly Revenue Growth YOY
7.3%
Gross Profit TTM
16.5M
EBITDA
-35.6M
Diluted Eps TTM
-1.56
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.8
EPS Estimate Next Year
-1.69
EPS Estimate Current Quarter
-0.53
EPS Estimate Next Quarter
-0.54

Analyst Recommendation

Buy
    90%Buy
    10%Hold
    0
    0%Sell
Based on 10 Wall street analysts offering stock ratings for DURECT Corp(by analysts ranked 0 to 5 stars)
Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
9
9
8
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 463.76%

Current $6.43
Target $36.25

Company Financials

FY17Y/Y Change
Revenue
49.2M
↑ 250.59%
Net Income
-3.7M
↓ 89.29%
Net Profit Margin
-7.51%
↑ 238.54%
FY18Y/Y Change
Revenue
18.6M
↓ 62.25%
Net Income
-25.3M
↑ 585.3%
Net Profit Margin
-136.4%
↓ 128.89%
FY19Y/Y Change
Revenue
29.6M
↑ 59.25%
Net Income
-20.6M
↓ 18.73%
Net Profit Margin
-69.6%
↑ 66.8%
FY20Y/Y Change
Revenue
30.1M
↑ 1.85%
Net Income
-582.0K
↓ 97.17%
Net Profit Margin
-1.93%
↑ 67.67%
FY21Y/Y Change
Revenue
14.0M
↓ 53.58%
Net Income
-36.3M
↑ 6131.1%
Net Profit Margin
-259.46%
↓ 257.53%
FY22Y/Y Change
Revenue
19.3M
↑ 37.96%
Net Income
-35.3M
↓ 2.57%
Net Profit Margin
-183.23%
↑ 76.23%
Q4 FY21Q/Q Change
Revenue
617.0K
↓ 71.5%
Net Income
-7.0M
↓ 29.76%
Net Profit Margin
-1.1K%
↓ 674.99%
Q1 FY22Q/Q Change
Revenue
1.9M
↑ 210.37%
Net Income
-10.8M
↑ 54.71%
Net Profit Margin
-566.16%
↑ 569.66%
Q2 FY22Q/Q Change
Revenue
2.1M
↑ 8.41%
Net Income
-11.6M
↑ 6.54%
Net Profit Margin
-556.41%
↑ 9.75%
Q3 FY22Q/Q Change
Revenue
12.0M
↑ 476.93%
Net Income
-2.5M
↓ 78.61%
Net Profit Margin
-20.63%
↑ 535.78%
Q4 FY22Q/Q Change
Revenue
3.3M
↓ 72.32%
Net Income
-10.5M
↑ 323.67%
Net Profit Margin
-315.81%
↓ 295.18%
Q1 FY23Q/Q Change
Revenue
2.1M
↓ 38.04%
Net Income
-12.0M
↑ 14.5%
Net Profit Margin
-583.59%
↓ 267.78%
FY17Y/Y Change
Total Assets
53.1M
↑ 31.12%
Total Liabilities
31.6M
↓ 1.69%
FY18Y/Y Change
Total Assets
50.0M
↓ 5.86%
Total Liabilities
30.0M
↓ 5.14%
FY19Y/Y Change
Total Assets
86.0M
↑ 72.04%
Total Liabilities
63.2M
↑ 110.54%
FY20Y/Y Change
Total Assets
75.6M
↓ 12.07%
Total Liabilities
35.5M
↓ 43.75%
FY21Y/Y Change
Total Assets
92.0M
↑ 21.61%
Total Liabilities
12.7M
↓ 64.27%
FY22Y/Y Change
Total Assets
60.1M
↓ 34.67%
Total Liabilities
35.1M
↑ 176.67%
Q4 FY21Q/Q Change
Total Assets
92.0M
↓ 6.1%
Total Liabilities
12.7M
↓ 62.6%
Q1 FY22Q/Q Change
Total Assets
80.5M
↓ 12.46%
Total Liabilities
32.9M
↑ 159.41%
Q2 FY22Q/Q Change
Total Assets
70.0M
↓ 13.1%
Total Liabilities
33.3M
↑ 1.07%
Q3 FY22Q/Q Change
Total Assets
68.5M
↓ 2.15%
Total Liabilities
33.6M
↑ 1.03%
Q4 FY22Q/Q Change
Total Assets
60.1M
↓ 12.23%
Total Liabilities
35.1M
↑ 4.45%
Q1 FY23Q/Q Change
Total Assets
58.3M
↓ 2.91%
Total Liabilities
43.0M
↑ 22.47%
FY17Y/Y Change
Operating Cash Flow
-1.3M
↓ 95.08%
Investing Cash Flow
12.7M
↑ 110.2%
Financing Cash Flow
12.6M
↓ 45.3%
FY18Y/Y Change
Operating Cash Flow
-19.8M
↑ 1370.59%
Investing Cash Flow
4.5M
↓ 64.25%
Financing Cash Flow
17.5M
↑ 38.48%
FY19Y/Y Change
Operating Cash Flow
11.1M
↓ 156.21%
Investing Cash Flow
-27.3M
↓ 702.25%
Financing Cash Flow
19.5M
↑ 11.56%
FY20Y/Y Change
Operating Cash Flow
-38.7M
↓ 448.65%
Investing Cash Flow
9.4M
↓ 134.52%
Financing Cash Flow
15.7M
↓ 19.7%
FY21Y/Y Change
Operating Cash Flow
-37.3M
↓ 3.6%
Investing Cash Flow
15.3M
↑ 62.33%
Financing Cash Flow
50.5M
↑ 222.68%
Q4 FY21Q/Q Change
Operating Cash Flow
-11.1M
↑ 50.99%
Investing Cash Flow
5.4M
↓ 20.88%
Financing Cash Flow
151.0K
↓ 229.06%
Q1 FY22Q/Q Change
Operating Cash Flow
-5.6M
↓ 49.97%
Investing Cash Flow
5.1M
↓ 4.54%
Financing Cash Flow
8.0K
↓ 94.7%
Q2 FY22Q/Q Change
Operating Cash Flow
-10.1M
↑ 81.35%
Investing Cash Flow
7.8M
↑ 50.57%
Financing Cash Flow
26.0K
↑ 225.0%
Q3 FY22Q/Q Change
Operating Cash Flow
-2.2M
↓ 77.89%
Investing Cash Flow
5.5M
↓ 29.51%
Financing Cash Flow
25.0K
↓ 3.85%
Q1 FY23Q/Q Change
Operating Cash Flow
-9.3M
↑ 10.13%
Investing Cash Flow
-4.9M
-
Financing Cash Flow
10.0M
↑ 41566.67%

Technicals Summary

Sell

Neutral

Buy

DURECT Corp is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
DURECT Corp
DURECT Corp
43.33%
43.37%
994.55%
145.71%
207.14%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
-12.31%
-28.21%
-2.43%
-26.08%
-4.62%
Zoetis Inc.
Zoetis Inc.
-8.25%
6.88%
-3.62%
19.08%
95.07%
Viatris Inc.
Viatris Inc.
-2.67%
-17.41%
-25.75%
-44.25%
-44.25%
Catalent, Inc.
Catalent, Inc.
-25.94%
-25.95%
-63.98%
-51.57%
-7.2%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
DURECT Corp
DURECT Corp
NA
NA
-0.46
-1.8
-1.16
-0.32
0.0
0.63
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
147.13
147.13
1.87
1.93
0.04
0.08
0.0
17.28
Zoetis Inc.
Zoetis Inc.
37.27
37.27
3.53
5.4
0.45
0.13
0.01
9.72
Viatris Inc.
Viatris Inc.
5.8
5.8
NA
2.95
0.09
0.03
0.05
17.45
Catalent, Inc.
Catalent, Inc.
16.21
16.21
1.18
1.37
0.09
0.04
0.0
27.29
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
DURECT Corp
DURECT Corp
Buy
$147.4M
207.14%
NA
-187.82%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$8.9B
-4.62%
147.13
4.0%
Zoetis Inc.
Zoetis Inc.
Buy
$76.1B
95.07%
37.27
25.59%
Viatris Inc.
Viatris Inc.
Hold
$10.9B
-44.25%
5.8
12.05%
Catalent, Inc.
Catalent, Inc.
Buy
$6.7B
-7.2%
16.21
8.62%

Institutional Holdings

  • Bleichroeder LP

    10.77%

  • Lion Point Capital, LP

    5.83%

  • Vanguard Group Inc

    4.19%

  • Ingalls & Snyder LLC

    3.74%

  • Armistice Capital, LLC

    2.49%

  • CM Management, LLC

    1.63%

Corporate Announcements

  • DURECT Corp Earnings

    DURECT Corp’s price-to-earnings ratio stands at None

    Read More

Company Information

DURECT is a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and potentially lifesaving therapies based on its endogenous epigenetic regulator program. DUR-928, the company's lead drug candidate is in clinical development for the potential treatment of alcohol-associated hepatitis (AH) for which FDA has granted a Fast Track Designation, COVID-19 patients with acute liver or kidney injury, and non-alcoholic steatohepatitis (NASH). DURECT's proprietary drug delivery technologies are designed to enable new indications and enhanced attributes for small-molecule and biologic drugs. One late-stage product candidate in this category is POSIMIR® (bupivacaine sustained-release solution), an investigational locally-acting, non-opioid analgesic intended to provide up to three days of continuous pain relief after surgery.

Organization
DURECT Corp
Employees
75
CEO
Dr. James E. Brown D.V.M.
Industry
Health Technology

Discover More

FAQs